Production of β-lactamases (BLs) is the most widespread resistance mechanism adopted by bacteria to fight β-lactam antibiotics. The substrate spectrum of BLs has become increasingly broad, posing a serious health problem. Thus, there is an urgent need for novel BL inhibitors. Boronic acid transition-state analogues are able to reverse the resistance conferred by class A and C BLs. We describe a boronic acid analogue possessing interesting and potent broad-spectrum activity vs class A and C serine-based BLs. Starting from benzo(b)thiophene-2-boronic acid (BZBTH2B), a nanomolar non-β-lactam inhibitor of AmpC that can potentiate the activity of a third-generation cephalosporin against AmpC-producing resistant bacteria, we designed a novel broad-spectrum nanomolar inhibitor of class A and C BLs. Structure-based drug design (SBDD), synthesis, enzymology data, and X-ray crystallography results are discussed. We clarified the inhibitor binding geometry responsible for broad-spectrum activity vs serine-active BLs using double mutant thermodynamic cycle studies. © 2014 American Chemical Society.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative|
|Citazione:||Tondi, D., Venturelli, A., Bonnet, R., Pozzi, C., Shoichet, B.K., & Costi, M.P. (2014). Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative. JOURNAL OF MEDICINAL CHEMISTRY, 57(12), 5449-5458.|
|Appare nelle tipologie:||1.1 Articolo in rivista|